BACKGROUND: Zoledronic acid, a bisphosphonate, delays progression of bone metastases in adult malignancies. Bone is a common metastatic site of advanced neuroblastoma. We previously reported efficacy of zoledronic acid in a murine model of neuroblastoma bone invasion prompting this Phase I trial of zoledronic acid with cyclophosphamide in children with neuroblastoma and bone metastases. The primary objective was to determine recommended dosing of zoledronic acid for future trials. PROCEDURE: Escalating doses of intravenous zoledronic acid were given every 28 days with oral metronomic cyclophosphamide (25 mg/m(2)/day). Toxicity, response, zoledronic acid pharmacokinetics, bone turnover markers, serum IL-6, and sIL-6R were evaluated. RESULTS: Twenty-one patients, median age 7.5 (range 0.8-25.6) years were treated with 2 mg/m(2) (n = 4), 3 mg/m(2) (n = 3), or 4 mg/m(2) (n = 14) zoledronic acid. Fourteen patients were evaluable for dose escalation. A median of one (range 1-18) courses was given. Two dose limiting toxicities (grade 3 hypophosphatemia) occurred at 4 mg/m(2) zoledronic acid. Other grades 3-4 toxicities included hypocalcemia (n = 2), elevated transaminases (n = 1), neutropenia (n = 2), anemia (n = 1), lymphopenia (n = 1), and hypokalemia (n = 1). Osteosclerosis contributed to fractures in one patient after 18 courses. Responses in evaluable patients included 1 partial response, 9 stable disease (median 4.5 courses, range 3-18), and 10 progressions. Zoledronic acid pharmacokinetics were similar to adults. Markers of osteoclast activity and serum IL-6 levels decreased with therapy. CONCLUSIONS: Zoledronic acid with metronomic cyclophosphamide is well tolerated with clinical and biologic responses in recurrent/refractory neuroblastoma. The recommended dose of zoledronic acid is 4 mg/m(2) every 28 days.
BACKGROUND:Zoledronic acid, a bisphosphonate, delays progression of bone metastases in adult malignancies. Bone is a common metastatic site of advanced neuroblastoma. We previously reported efficacy of zoledronic acid in a murine model of neuroblastoma bone invasion prompting this Phase I trial of zoledronic acid with cyclophosphamide in children with neuroblastoma and bone metastases. The primary objective was to determine recommended dosing of zoledronic acid for future trials. PROCEDURE: Escalating doses of intravenous zoledronic acid were given every 28 days with oral metronomic cyclophosphamide (25 mg/m(2)/day). Toxicity, response, zoledronic acid pharmacokinetics, bone turnover markers, serum IL-6, and sIL-6R were evaluated. RESULTS: Twenty-one patients, median age 7.5 (range 0.8-25.6) years were treated with 2 mg/m(2) (n = 4), 3 mg/m(2) (n = 3), or 4 mg/m(2) (n = 14) zoledronic acid. Fourteen patients were evaluable for dose escalation. A median of one (range 1-18) courses was given. Two dose limiting toxicities (grade 3 hypophosphatemia) occurred at 4 mg/m(2) zoledronic acid. Other grades 3-4 toxicities included hypocalcemia (n = 2), elevated transaminases (n = 1), neutropenia (n = 2), anemia (n = 1), lymphopenia (n = 1), and hypokalemia (n = 1). Osteosclerosis contributed to fractures in one patient after 18 courses. Responses in evaluable patients included 1 partial response, 9 stable disease (median 4.5 courses, range 3-18), and 10 progressions. Zoledronic acid pharmacokinetics were similar to adults. Markers of osteoclast activity and serum IL-6 levels decreased with therapy. CONCLUSIONS:Zoledronic acid with metronomic cyclophosphamide is well tolerated with clinical and biologic responses in recurrent/refractory neuroblastoma. The recommended dose of zoledronic acid is 4 mg/m(2) every 28 days.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Luis Costa; Laurence M Demers; A Gouveia-Oliveira; J Schaller; Eduardo B Costa; Miguel C de Moura; Allan Lipton Journal: J Clin Oncol Date: 2002-02-01 Impact factor: 44.544
Authors: M Colleoni; A Rocca; M T Sandri; L Zorzino; G Masci; F Nolè; G Peruzzotti; C Robertson; L Orlando; S Cinieri; Braud F de; G Viale; A Goldhirsch Journal: Ann Oncol Date: 2002-01 Impact factor: 32.976
Authors: J R Berenson; L S Rosen; A Howell; L Porter; R E Coleman; W Morley; R Dreicer; S A Kuross; A Lipton; J J Seaman Journal: Cancer Date: 2001-04-01 Impact factor: 6.860
Authors: L Giannitrapani; M Cervello; M Soresi; M Notarbartolo; M La Rosa; L Virruso; N D'Alessandro; G Montalto Journal: Ann N Y Acad Sci Date: 2002-06 Impact factor: 5.691
Authors: Fred Saad; Donald M Gleason; Robin Murray; Simon Tchekmedyian; Peter Venner; Louis Lacombe; Joseph L Chin; Jeferson J Vinholes; J Allen Goas; Bee Chen Journal: J Natl Cancer Inst Date: 2002-10-02 Impact factor: 13.506
Authors: B A Lenart; A S Neviaser; S Lyman; C C Chang; F Edobor-Osula; B Steele; M C H van der Meulen; D G Lorich; J M Lane Journal: Osteoporos Int Date: 2008-12-09 Impact factor: 4.507
Authors: T Ponnapakkam; R Katikaneni; T Nichols; G Tobin; J Sakon; O Matsushita; R C Gensure Journal: J Endocrinol Invest Date: 2011-07-12 Impact factor: 4.256
Authors: A Bertaina; A Zorzoli; A Petretto; G Barbarito; E Inglese; P Merli; C Lavarello; L P Brescia; B De Angelis; G Tripodi; L Moretta; F Locatelli; I Airoldi Journal: Oncoimmunology Date: 2016-09-27 Impact factor: 8.110
Authors: Robert E Goldsby; Timothy M Fan; Doojduen Villaluna; Lars M Wagner; Michael S Isakoff; James Meyer; R Lor Randall; Sharon Lee; Grace Kim; Mark Bernstein; Richard Gorlick; Mark Krailo; Neyssa Marina Journal: Eur J Cancer Date: 2013-05-07 Impact factor: 9.162
Authors: Tasnim Ara; Rie Nakata; Michael A Sheard; Hiroyuki Shimada; Ralf Buettner; Susan G Groshen; Lingyun Ji; Hua Yu; Richard Jove; Robert C Seeger; Yves A DeClerck Journal: Cancer Res Date: 2013-04-30 Impact factor: 12.701